Autologous fat transfer after breast cancer surgery: An exact-matching study on the long-term oncological safety
ConclusionAFT does not increase breast cancer recurrence, with the possible exception of late LRRs for Luminal A patients, but further clinical and preclinical data are required to better clarify this data. The use of AFT should not be discouraged.
Publication date: Available online 22 June 2019Source: Journal of Geriatric OncologyAuthor(s): Etienne Brain, Philippe Caillet, Nienke de Glas, Laura Biganzoli, Karis Cheng, Lissandra Dal Lago, Hans WildiersAbstractHER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones. Many older patients have cardiovascular comorbidity and risk greater toxicity from therapy. Treatment therefore requires careful consideration, especially since trials include few patients over 65 and so provide limited guidance. A multidisciplinary task force of the International Society of Geriatric Oncology cond...
Dr Harold Burstein highlights ASCO oral presentations on early breast cancer, featuring neoadjuvant therapy in HER2-positive disease and updated data from the TAILORx study in HR-positive disease.Medscape
CONCLUSION: This is the first reported Australian experience using neoadjuvant dual anti-HER2 and taxane therapy for HER-2 positive nonmetastatic breast cancer. The authors have demonstrated favorable pCR rates for invasive disease compared to the NEOSPHERE trial (68% vs 46%), with reasonable patient tolerability. Larger collaborative data sets are required to fully evaluate correlation of pCR with survival outcomes, and cost-effectiveness. National funding models need to be considered. PMID: 31218842 [PubMed - as supplied by publisher]
ner S Abstract BACKGROUND: and purpose: To investigate incidence and location of locoregional recurrence (LRR) in patients who have received postoperative locoregional radiotherapy (LRRT) for primary breast cancer. LRR-position in relation to applied radiotherapy and the primary tumours biological subtype were analysed with the aim to evaluate current target guidelines and RT techniques in relation to tumour biology. MATERIALS AND METHODS: Medical records were reviewed for all patients who received postoperative LRRT for primary BC in southwestern Sweden from 2004-2008 (N=923). Patients with LRR as a first ev...
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
Publication date: Available online 12 June 2019Source: European Journal of RadiologyAuthor(s): G Santamaría, X Bargalló, S G Ganau, I Alonso, M Muñoz, M Mollà, PL Fernández, A PratABSTRACTOBJECTIVES: To validate the performance of multiparametric magnetic resonance (MR) imaging to assess pathologic response to neoadjuvant systemic therapy (NST) in various breast cancer subtypes considering two definitions of pCR: absence of any residual invasive cancer or DCIS (ypT0) and absence of invasive tumour cells (ypT0/is).METHODSInstitutional review board–approved retrospective study, with w...
Conclusions: The use of CT information during boost field planning could reduce the risk of LR among patients undergoing BCT. Neoadjuvant and adjuvant treatments for breast cancer did not show the significant difference in respect to the outcome of LR.
CONCLUSION: The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis. Therefore, the absence of ER should be considered as important factor in determining the treatment strategy. PMID: 31204155 [PubMed - as supplied by publisher]
Condition: Breast Cancer Interventions: Drug: Apatinib; Drug: Paclitaxel; Drug: Cisplatin; Procedure: Surgery Sponsor: RenJi Hospital Recruiting